Cytokines in New‐Onset Refractory Status Epilepticus Predict Outcomes
Annals of Neurology · 2023-07 · 94 (1) · 75-90
DOI: 10.1002/ana.26627 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Neurology, online erschienen am 17.03.2023. Verfasst von Aurélie Hanin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Immunobiology, Yale University School of Medicine, New Haven, CT, United States. Hauptthemen laut MEDLINE: Cytokines, Status Epilepticus. Die Arbeit wurde bisher 125-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: NCI NIH HHS, Philippe Foundation, Institut Servier.
Abstract (Originalsprache)
Objective
The objective of this study was to investigate inflammation using cerebrospinal fluid (CSF) and serum cytokines/chemokines in patients with new‐onset refractory status epilepticus (NORSE) to better understand the pathophysiology of NORSE and its consequences.
Methods
Patients with NORSE (n = 61, including n = 51 cryptogenic), including its subtype with prior fever known as febrile infection‐related epilepsy syndrome (FIRES), were compared with patients with other refractory status epilepticus (RSE; n = 37), and control patients without SE (n = 52). We measured 12 cytokines/chemokines in serum or CSF samples using multiplexed fluorescent bead‐based immunoassay detection. Cytokine levels were compared between patients with and without SE, and between the 51 patients with cryptogenic NORSE (cNORSE) and the 47 patients with a known‐etiology RSE (NORSE n = 10, other RSE n = 37), and correlated with outcomes.
Results
A significant increase of IL‐6, TNF‐α, CXCL8/IL‐8, CCL2, MIP‐1α, and IL‐12p70 pro‐inflammatory cytokines/chemokines was observed in patients with SE compared with patients without SE, in serum and CSF. Serum innate immunity pro‐inflammatory cytokines/chemokines (CXCL8, CCL2, and MIP‐1α) were significantly higher in patients with cNORSE compared to non‐cryptogenic RSE. Patients with NORSE with elevated innate immunity serum and CSF cytokine/chemokine levels had worse outcomes at discharge and at several months after the SE ended.
Interpretation
We identified significant differences in innate immunity serum and CSF cytokine/chemokine profiles between patients with cNORSE and non‐cryptogenic RSE. The elevation of innate immunity pro‐inflammatory cytokines in patients with NORSE correlated with worse short‐ and long‐term outcomes. These findings highlight the involvement of innate immunity‐related inflammation, including peripherally, and possibly of neutrophil‐related immunity in cNORSE pathogenesis and suggest the importance of utilizing specific anti‐inflammatory interventions. ANN NEUROL 2023;94:75–90
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology and Immunobiology, Yale University School of Medicine, New Haven, CT, United States.
- Sorbonne Université, Institut du Cerveau, Paris Brain Institute, ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France.
- Department of Clinical Neurophysiology, Epilepsy Unit, DMU Neurosciences 6, AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France.
- Comprehensive Epilepsy Center, Department of Neurology, Yale University School of Medicine, New Haven, CT, United States.
- Universidad Autonoma de Centro America, School of Medicine, San Jose, Costa Rica.
- Department of Immunology, Sorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses, AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France.
ORCID-Profile: Aurélie Hanin, Jorge Cespedes, Karim Dorgham, Vincent Navarro, Nicolas Gaspard, Lawrence J Hirsch
Förderung
- NCI NIH HHS
- Philippe Foundation
- Institut Servier
Zitieren
APA
Hanin, A., Cespedes, J., Dorgham, K., Pulluru, Y., Gopaul, M., Gorochov, G., Hafler, D. A., Navarro, V., Gaspard, N., & Hirsch, L. J. (2023). Cytokines in New‐Onset Refractory Status Epilepticus Predict Outcomes. Annals of Neurology, 94(1), 75-90. https://doi.org/10.1002/ana.26627
Vancouver
Hanin A, Cespedes J, Dorgham K, Pulluru Y, Gopaul M, Gorochov G, et al. Cytokines in New‐Onset Refractory Status Epilepticus Predict Outcomes. Annals of Neurology. 2023;94(1):75-90. doi:10.1002/ana.26627
BibTeX
@article{Hanin2023,
author = {Hanin, Aurélie and Cespedes, Jorge and Dorgham, Karim and Pulluru, Yashwanth and Gopaul, Margaret and Gorochov, Guy and Hafler, David A and Navarro, Vincent and Gaspard, Nicolas and Hirsch, Lawrence J},
title = {Cytokines in New‐Onset Refractory Status Epilepticus Predict Outcomes},
journal = {Annals of Neurology},
year = {2023},
volume = {94},
number = {1},
pages = {75--90},
doi = {10.1002/ana.26627}
}
EUVIMED